Article
Revisiting the Mesenchymal “Stem vs. Stromal” Cell Dichotomy and Its Implications for Development of Improved Potency Metrics
8 Mar 2023
Abstract excerpt
Mesenchymal stem/stromal cell (MSC)-based therapies have been evaluated in over 1500 human clinical trials for a diverse array of disease indication, but outcomes remain unpredictable due to knowledge gaps in the quality attributes that confer therapeutic potency onto cells and their mode of action in vivo. Based on accumulated evidence from pre-clinical models, MSCs exert therapeutic effects by repressing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
